Article

Percutaneous nephrolithotomy: Tricks and tips for access and stone removal

Although percutaneous nephrolithotomy (PCNL) comprises only 4% to 6% of all stone surgeries, it behooves the urologist with an interest in stone disease to be facile in this treatment modality in order to offer patients the most appropriate and effective treatment for their stones.

 

 

Preoperative imaging

 

 

 

 

Selecting the optimal calyx for puncture

 

Related Videos
Perry Xu, MD, answers a question during a Zoom video interview
Kate H. Kraft, MD, MHPE, FACS, FAAP, answers a question during a Zoom video interview
Hailey Frye answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Thomas Chi, MD, MBA, answers a question during a Zoom video interview
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Related Content
FDA reports Urgent Device Field Correction notice for CVAC Aspiration System
March 21st 2025

FDA reports Urgent Device Field Correction notice for CVAC Aspiration System

Hannah Clarke
Calyxo has identified a new risk of injury when the CVAC System is used in patients with high viscosity fluid in their kidneys at the start of the procedure.
Why kidney stones will become more prevalent over time
February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff
“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.
Kidney stone prevalence is increasing in women, study findings show
March 17th 2025

Kidney stone prevalence is increasing in women, study findings show

Hannah Clarke
The overall prevalence of kidney stones remained stable, with a notable increase observed among women.
Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters
September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff
“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.
YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1
February 25th 2025

YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1

Hannah Clarke
YOLT-203 was granted an Orphan Drug Designation and a Rare Pediatric Disease Designation in September 2024.
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke
A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.
© 2025 MJH Life Sciences

All rights reserved.